HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetics Provisions Unlikely To Catch Ride On FDA User-Fee Bill

This article was originally published in The Rose Sheet

Executive Summary

With the release of an atypically lean, clean FDA user-fee reauthorization draft bill, it’s doubtful that cosmetics regulatory reform language will get tacked onto the must-pass legislation. Stakeholders likely will refocus their efforts on standalone cosmetics legislation to modernize FDA’s oversight of the industry.

You may also be interested in...



Surprise Hatch Bill Lays Middle Ground For Cosmetic Regulatory Reform

Senator Orrin Hatch, R-Utah, introduces the FDA Cosmetic Safety and Modernization Act with the Personal Care Products Council's backing. The Environmental Working Group is opposed to the proposal, which falls considerably short of the draft Personal Care Products Safety Act, but the bill could unite big and small business, which were divided in the previous Congress with respect to regulatory reform legislation.

Cosmetics Reform Bill Relaunches In Senate, Sending Stakeholders To Familiar Corners

The Personal Care Products Safety Act introduced in the Senate May 11, and the Cosmetic Modernization Amendments Act that launched in the House earlier this year, closely mirror versions that divided big and small business in the last Congress. So while the US political environment may be dramatically changed, the legislative situation for stakeholders seeking updated cosmetics regulations, at the moment, is not.

Gottlieb Becomes FDA Commissioner With Immediate Issues Pending

Confirmation comes with fewest votes of any recent commissioner as FDA faces pressing budget, user-fee and other issues. The Personal Care Products Council welcomed Gottlieb to the post and took the occasion to plug cosmetics industry virtues at a time when legislation is under consideration to update regulations.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel